The bill:
- Allows for the sale of products containing CBD derived from hemp.
- Requires products containing hemp-derived CBD to be registered annually by the manufacturer.
- Creates a position in the Department of Agriculture, Markets, and Food to perform inspections relative to registered products containing CBD derived from hemp.
The comments continue: “NPA and our member companies are concerned that without a clear regulatory pathway in place, tainted products will continue to enter the marketplace, leaving consumers susceptible to harm and discouraging legitimate companies from engaging in interstate commerce…While we believe regulatory standards from the FDA are the best way to move forward with this promising new comments while protecting consumers, we are supportive of the standards outlined in this legislation.”
Related: CV Sciences Contributes to First Special Issue on Cannabinoids MA Legislature Considers Bill Restricting Access to Supplements Coalition to Congress: Include Tax Credit to Help Businesses Absorb COVID-19 Costs
The press release notes that NPA has helped craft legislation passed by the U.S. House of Representatives that provides resources so the FDA can perform a Health Hazard Evaluation and set a safe level of CBD consumption.“This is a federal regulatory issue, FDA needs to do its job, and they need to do it now. While it is good that more states realize the public health risk of completely unregulated products in the marketplace, further delay by FDA is not good for public health or for the CBD industry, because the best approach is one uniform national standard based on sound science that is enforceable,” said NPA Director for Government Affairs Kyle Turk in the press release.